PRMT5 and Glutamine Vulnerability in Neuroblastoma

2026-10-06

Bojko and colleagues show that MYCN-amplified neuroblastoma is unusually sensitive to PRMT5 inhibition through interconnected changes in RNA splicing, epitranscriptomic regulation, and glutamine metabolism. The study provides a mechanistic framework for cancer metabolism research while indicating that direct glutaminase inhibition remains a related but distinct question for preclinical cancer drug evaluation.

How Transcription Termination Limits WEE1-Inhibitor Damage

2026-10-06

BRD4–RAC1 Co-targeting in Breast Cancer

2026-10-05

A 2021 study reports that combined BRD4 and RAC1 inhibition suppresses breast cancer growth, stemness, migration, and xenograft tumorigenesis while disrupting the c-MYC–G9a–FTH1 axis and reducing HDAC1-associated signaling. The findings support a subtype-aware, mechanistic framework for studying how transcriptional and epigenetic dependencies interact, but remain preclinical and require validation beyond the models examined.

3-Hydroxybutyrate (BHBA): Evidence Overview

2026-10-04

3-Hydroxybutyrate, also called BHBA, is a ketone-body metabolite linking energy metabolism with cellular signaling. Preclinical stroke research suggests that ketone-body responses may be associated with reduced ferroptosis, but the available study does not establish that BHBA alone caused the observed neuroprotection. This overview separates reported findings from interpretation and outlines the major evidence limitations.

PRMT5, Splicing, and Metabolic Vulnerability in Neuroblastom

2026-10-03

Bojko and colleagues connect PRMT5-dependent spliceosomal disruption with epitranscriptomic remodeling and impaired glutamine metabolism in MYCN-amplified neuroblastoma. Their integrated cellular, transcriptomic, isotope-tracing, protein, and mouse-model evidence identifies GLS regulation as a mechanistic consequence of PRMT5 inhibition, while also defining important boundaries for translation and downstream drug evaluation.

Degarelix Acetate in Prostate Cancer: Evidence

2026-10-02

Klotz’s review presents degarelix acetate as a clinically important refinement of androgen-deprivation therapy because direct GnRH-receptor antagonism suppresses testosterone without the initial surge associated with GnRH agonists. Its synthesis of phase II and phase III evidence emphasizes rapid testosterone and PSA responses, while also clarifying injection-site tolerability and the limits of short-term surrogate outcomes.

hCG, H3K27 Methylation, and CXCL10 in Decidua

2026-10-01

The reference study defines a chromatin-based mechanism by which trophoblast-derived human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells. Its central contribution is linking hCG, EZH2-dependent H3K27me3 deposition, reduced CD8-cell recruitment, and immune regulation at the maternal–fetal interface.

GSK J4 HCl: JMJD3 Workflow and Applications

2026-10-01

GSK J4 HCl supports mechanism-first studies that connect JMJD3 activity with H3K27 methylation, cytokine output, and tumor biology. This guide translates the decidual CXCL10 study into practical chromatin, inflammation, and glioma workflows while emphasizing controls and troubleshooting.

EPZ5676: DOT1L Inhibitor Workflow Guide

2026-09-30

Build a mechanism-led workflow around EPZ5676 for DOT1L activity profiling, H3K79 methylation inhibition, and MLL-rearranged leukemia models. This guide connects biochemical assays with cellular validation while emphasizing solvent control, SAM competition, orthogonal readouts, and practical troubleshooting.

RESTRICT-seq Maps Epigenetic SCC Resistance

2026-09-30

The preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy designed to distinguish epigenetic dependencies that arise during squamous cell carcinoma resistance from vulnerabilities present before resistance develops. Its main contribution is methodological: aligning genetic perturbation with disease-state timing provides a more informative framework for discovering resistance-associated dependencies and prioritizing follow-up experiments.

Rocilinostat (ACY-1215): Workflow Guide

2026-09-29

Build cleaner HDAC6-centered experiments with Rocilinostat (ACY-1215), from α-tubulin acetylation and multiple myeloma cell viability assays to proteasome-inhibitor combination studies. A separate neurodevelopment application shows how the compound can support carefully bounded cilia and neural-progenitor hypotheses without overstating cross-domain evidence.

Tiamulin Workflows for Veterinary Research

2026-09-29

Tiamulin (Thiamutilin) combines pleuromutilin antibacterial activity with investigational anti-inflammatory effects, making it useful for susceptibility, cell-signaling, and pharmacokinetic workflows. This guide translates those properties into practical assay design, formulation controls, PK/PD interpretation, and troubleshooting for veterinary research.

hCG–EZH2–CXCL10 Signaling in Human Decidua

2026-09-28

The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells through EZH2-dependent deposition of the repressive H3K27me3 mark. By connecting hormone signaling, promoter-localized chromatin remodeling, and CD8-cell recruitment, the work provides a mechanistic framework for understanding immune regulation at the maternal–fetal interface.

From SIRT1 Biology to Bone-Regeneration Strategy

2026-09-28

A translational perspective on how SIRT1 links vascular and osteogenic function in aging bone—and how researchers can rigorously evaluate SRT1720 HCl as a tool for testing that biology.

SP2509 and LSD1: Interpreting Epigenetic Dependencies

2026-09-27

SP2509 is a potent Lysine-specific demethylase 1 antagonist for studying how LSD1-linked chromatin regulation shapes cancer-cell states. This article connects its AML evidence to a breast-cancer study of BRD4–RAC1 co-targeting while clarifying what that cross-domain comparison can—and cannot—tell researchers.